21,838 Gilead Sciences, Inc. $GILD Shares Sold by Diversified Trust Co

Diversified Trust Co reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 39.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,796 shares of the biopharmaceutical company’s stock after selling 21,838 shares during the quarter. Diversified Trust Co’s holdings in Gilead Sciences were worth $5,037,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Aberdeen Group plc lifted its stake in Gilead Sciences by 3.1% in the 3rd quarter. Aberdeen Group plc now owns 1,034,855 shares of the biopharmaceutical company’s stock worth $154,245,000 after purchasing an additional 31,340 shares in the last quarter. Compass Capital Management Inc. purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at $245,000. Valmark Advisers Inc. grew its position in shares of Gilead Sciences by 4.0% during the 3rd quarter. Valmark Advisers Inc. now owns 3,391 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 130 shares in the last quarter. Allworth Financial LP grew its position in shares of Gilead Sciences by 6.4% during the 3rd quarter. Allworth Financial LP now owns 50,207 shares of the biopharmaceutical company’s stock valued at $7,483,000 after purchasing an additional 3,015 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in shares of Gilead Sciences by 1,516.0% in the third quarter. Fisher Asset Management LLC now owns 305,850 shares of the biopharmaceutical company’s stock worth $45,587,000 after purchasing an additional 286,924 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Key Stories Impacting Gilead Sciences

Here are a few of the latest stories about GILD:

• Positive Sentiment: Zacks Research raised several forecasts, including FY2027 EPS to $9.42 from $9.36 and FY2028 EPS to $9.69 from $9.66. It also made small upward adjustments to quarterly estimates. The revisions suggest slightly improved expectations, though the analyst’s Hold rating tempers the signal.
• Positive Sentiment: Coverage points to momentum in Gilead’s HIV franchise: Yeztugo sales are described as surging, Biktarvy remains a market leader, and the expanding pipeline could support longer-term growth. Read More..
• Neutral Sentiment: Gilead announced a partnership with TelevisaUnivision to promote HIV-prevention awareness at the Latin GRAMMY Awards. It may build awareness, but the announcement does not specify a direct near-term financial impact. Read More..

Insider Activity at Gilead Sciences

In related news, EVP Keeley Cain Wettan sold 3,399 shares of the company’s stock in a transaction on Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the transaction, the executive vice president directly owned 5,360 shares in the company, valued at approximately $879,629.60. The trade was a 38.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 9,810 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the completion of the transaction, the chief executive officer owned 551,683 shares of the company’s stock, valued at $96,638,311.11. This trade represents a 1.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 242,709 shares of company stock valued at $39,503,427. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $168.08 on Friday. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84. The company has a 50 day simple moving average of $155.10 and a two-hundred day simple moving average of $141.80.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.47 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.98 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s payout ratio is currently -103.80%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent analyst reports. Scotiabank increased their price objective on Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 30th. BMO Capital Markets reissued an “outperform” rating and set a $184.00 price objective on shares of Gilead Sciences in a research note on Friday, October 30th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research report on Friday, October 30th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, TD Cowen upped their target price on Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $171.07.

Gilead Sciences Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.